Biotech Leaders

More big biotech annoucements!

Exciting news today!!

🏅 Exciting times in biotech, just as the Paris Olympics are set to begin! 🌟 Javelin Biotech appoints Jacques Banchereau as Chief Scientific Officer, bringing world-class expertise to their innovative team. 🤝 Relay Therapeutics is collaborating with Pfizer to evaluate new breast cancer treatments, aiming for breakthroughs that could be as monumental as an Olympic gold. 💰 Bicycle Therapeutics achieves a major milestone with a $555M PIPE raise, fueling their journey to revolutionize healthcare. Just as athletes are set to push boundaries in Paris over the next few weeks, these companies are pushing the limits of science and medicine. Onward and upward! 🧬✨ #Biotech #HealthcareInnovation #Paris2024 #Olympics #JavelinBiotech #RelayTherapeutics #BicycleTherapeutics #Pfizer

📅 Friday Biotech company showcase shout-out, todays innovator The Netherlands based Biotech Scenic Biotech 🌟 Scenic Biotech is advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another function in the genome that can neutralize the disease impact, leading to a therapeutic effect. Their robust pipeline, derived from their proprietary Cell-seq™️ platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic will develop a range of modifier therapies to help patients. ✨ Scenic Biotech entered into a collaboration with Bristol Myers Squibb earlier in the year and Oscar Izeboud is set to give an exciting presentation. If you're interested in being a part of this fantastic agenda of innovators, don't hesitate to reach out. #biotech #investment #partnering #lsxusa #pharma

🚨🔥 HOT OFF THE PRESS 🔥🚨 Flagship Pioneering, which launched Moderna, has secured $3.6bn in funding to create new biotechs using AI 🤖 for drug discovery. The firm raised $2.6bn for its eighth fund and $1bn for sector-specific investments, focusing heavily on AI-driven drug development. With $14bn in assets, Flagship is one of the major biotech investors in the US, generating and building startups before bringing in outside investors 🚀 Come and meet Flagship Pioneering at the LSX USA Congress this Sept 11-12, Boston. Very excited to have Steve Hahn and Bernard Cooney speaking on the future of drugs, devices, and digital, and the current biotech investment landscape! #AI #RNA #LSXUSA #biotech

Happy July everyone, I hope we are all gearing up for some celebrations tomorrow 🎆 but in the mean time here is Biotech Company showcase #5 Gero 🌟 Gero is a preclinical-stage target & drug discovery company creating therapeutics for age-related diseases. Gero applies machine learning algorithms originating from the physics of complex systems to build clinically relevant disease progression models in real-world human data. Then we use molecular data such as Whole-Exome sequencing (or plasma proteomics) to RWD-based protective variants - therapeutic targets - potentially applicable to several indications simultaneously. The in-human drug discovery approach allows us to avoid the “preclinical trap” and select the most efficient targets against human (not mice) diseases. Gero has an active collaboration with Pfizer and their research has been published in Nature Communications and Science journals as well as covered by Scientific American and Popular Mechanics. ⭐ Whether you know Gero through their appearances at a conferences, their collaboration with Pfizer, multiple publications or even their shout out from the total 69 million follower social media pages Ladbible, Gero is becoming one of the best known names in the industry. We look forward to seeing you there Alexey Kadet #lsxusa #biotech #techbio #ai #investment #partnering

🔬 Happy Friday everyone, before we head off for the weekend its time for our next LSX USA Congress Biotech company showcase. Todays company Lisata Therapeutics, Inc. ⭐ Lisata Therapeutics, which was formed from the merger of Caladrius Biosciences and Cend Therapeutics, is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead investigational product candidate, certepetide, is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. Certepetide actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. Certepetide has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of certepetide to enable a variety of treatment modalities to treat a range of solid tumors more effectively. 🌟 Lisata is another long time attendee of ours and always gives a great presentation. We look forward to hearing from you again David J. Mazzo, Ph.D. and John Menditto #lsxusa #investment #biotech #pharma #immunotherpies #rna

Ready for a mid-week 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐁𝐮𝐥𝐥𝐞𝐭𝐢𝐧? 🌟 Cash galore this week as biotechs raise significant rounds, from Series A to Series E! 📈 🍄 Elion Therapeutics raises an $81 Million Series B from Deerfield Management, AMR Action Fund, and Illinois Ventures to advance clinical-stage candidate SF001, a next-gen polyene antifungal currently being studied in a multiple-ascending dose study - congrats Kieren Marr! 💉 Kudos to Prakash Raman at InduPro for the $85 Millon Series A, together from The Column Group, Vida Ventures, MRL Ventures Fund LLC, Emerson Collective, and EUCLIDEAN CAPITAL, LLC, advancing a first candidate into the clinic and and early-stage pipeline of bispecific antibodies and antibody drug conjugates that use protein proximity to identify novel tumor selective target pairings 🧠 Alzheon, Inc. | Preserving Future Memories raises a $100 Million Series E led by Alerce Medical Technology Partners to advance the company's investigational therapies and diagnostic assays for patients with Alzheimer’s disease and other neurodegenerative disorders ⛰️ Bright Peak Therapeutics raises a $90 Million Series C led by Johnson & Johnson Innovation JJDC Inc, and new investors Venrock, KB Investment, and Northleaf Capital Partners Follow us at Biotech Leaders for more industry updates! #biotech #investment #deals #capital

LSX USA Congress Biotech company showcase pt.3 OCMS Bio! 👨💻 Today we venture into the more 'techbio' side of Biotech 🌟OCMS Bio deploys a proprietary mammalian high throughput antibody discovery engine for the rapid development of patentable best-in-class fast-follower mAbs with improved efficacy for therapeutically proven high value targets.   Since launching this program in January, 3 validated preclinical leads (in infectious disease, oncology and human metabolism) are coming off our pipeline this summer with 6 more finishing in the next 18 months--each a marked improvement over an in market, best in class antibody.   These fast-follower best-in-class molecules offer increased efficacy, access and patient choice globally.🌟 Every presenting company does something different, but all are innovators driving the industry forward. Lets continue to Invest in Innovation! We look forward to welcoming you in September Paul Halpern #lsxusa #techbio #investment #biotech #antibodies #partnering #biopharma

🚨 Time for another LSX USA Congress Biotech Showcase company spotlight! 🔦 🔬 Vincere Biosciences, getting its name from the Latin to conquer, is ready to take on age related decline! 🌟Vincere Biosciences is at the forefront of discovering and developing small molecule therapeutics to safeguard high-energy tissues, including the brain, heart, and kidneys. Leveraging a combination of AI-driven tools, traditional biology and drug discovery expertise, Vincere targets fundamental causes of age-related decline. Pioneering compounds that enhance the elimination of damaged mitochondria, this innovative approach positions Vincere as a promising contender in addressing a spectrum of age-related conditions, from Parkinson’s disease to cardiorenal disorders. We look forward to welcoming Vincere Biosciences and Andy Lee to Boston this September, and are so excited to hear more about their work! #biotech #partnering #pharma #investors #networking #LSXUSA #therapeutics #ParkinsonsDisease